

No active trail

DELPHION

Select 1K

96

RESEARCH

PRODUCTS


INSIDE DELPHION

Log Out Web Files Search

My Account

Search: Quick/Number Boolean Advanced Der


The Delphion Integrated View

Get Now:  PDF | [File History](#) | [Other choices](#)Tools: [Add to Work File](#) | [Create new W](#)View: [Expand Details](#) | [INPADOC](#) | Jump to: Go to: [Derwent](#) 

Title: EP0722731B1: REMEDY FOR SPINOCEREBELLAR DEGENERATION[German][French]

Derwent Title: Agent for treating spino-cerebellar degeneration - esp. Machado-Joseph disease, is pterin deriv. esp. tetra:hydro-biopterin [\[Derwent Record\]](#)

Country: EP European Patent Office (EPO)

Kind: B1 Patent (See also: [EP0722731A1](#), [EP0722731A4](#))Inventor: SAKAI, Tetsuo;
ANTOKU, Yasunobu;
MATSUISHI, Toyojiro;Assignee: SUNTORY LIMITED
 [Corporate Tree data: Suntory Ltd. \(SUNTORY\);
News, Profiles, Stocks and More about this company](#)

Published / Filed: 2002-06-05 / 1995-08-04

Application Number: EP1995000927966

IPC Code: Advanced: [C07D 475/04](#);
Core: [C07D 475/00](#);
IPC-7: [A61K 31/505](#);
[C07D 475/04](#);

ECLA Code: C07D475/04;

Priority Number: 1994-08-05 JP1994000184682

Abstract: [From equivalent [EP0722731A1](#)] A remedy for spinocerebellar degeneration containing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient, wherein R1 and R2 represent each hydrogen or they are combined together to represent a single bond; and R3 represents -CH(OH)CH(CH)CH3, -CH(OCOCH3)CH(OCOCH3)CH3, -CH3, -CH2OH or phenyl when R1 and R2 represent each hydrogen, while R3 represents -COCH(OH)CH3 when R1 and R2 together represent a single bond. [French]

Attorney, Agent or Firm: Hansen, Bernd, Dr. Dipl.-Chem. ;








[Show legal status actions](#) Get Now: [Family Legal Status Report](#)

INPADOC

Legal Status:

Designated Country: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Family:

PDF	Publication	Pub. Date	Filed	Title
	WO9603989A1	1996-02-15	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION
	US5753656	1998-05-19	1995-08-04	Method for treating spinocerebellar degeneration
	JP02761104B2	1998-06-04	1995-08-04	SEKIZUISHONOHENSEISHOCHIRYOZAI
	ES2177654T3	2002-12-16	1995-08-04	REMEDI0 CONTRA LA DEGENERACION ESPINOCEREBE
	EP0722731B1	2002-06-05	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION
	EP0722731A4	1998-03-04	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION
	EP0722731A1	1996-07-24	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION

<input checked="" type="checkbox"/>	DE69526918T2	2002-12-19	1995-08-04	ARZNEIMITTEL GEGEN SPINOCEREBELLARE DEGENERATION
<input type="checkbox"/>	DE69526918C0	2002-07-11	1995-08-04	ARZNEIMITTEL GEGEN SPINOCEREBELLARE DEGENERATION
<input checked="" type="checkbox"/>	AT0218345E	2002-06-15	1995-08-04	ARZNEIMITTEL GEGEN SPINOCEREBELLARE DEGENERATION
10 family members shown above				

First Claim:
[Show all claims](#)

1. The use of a compound represented by the formula: wherein R¹ and R² each represents a hydrogen atom or, together, represent a single bond while R³ represents -CH(OH)CH(OH)CH₃, -CH(OCOCH₃)CH(OCOCH₃)CH₃, -CH₃, -CH₂OH or a phenyl group when R¹ and R² each represents a hydrogen atom, or -COCH(OH)CH₃ when R¹ and R² together represent a single bond or its salt for the preparation of a medicament useful for the treatment of spinocerebellar degeneration.
 [German] [French]

Description
[Expand description](#)

± **Background of the Invention**
 ± **Field of Application in Industry**

The present invention relates to the use of an agent for treating spinocerebellar degeneration containing as an effective ingredient a compound represented by the formula (I): wherein R¹ and R² each represents a hydrogen atom or, together, represent a single bond while R³ represents -CH(OH)CH(OH)CH₃, -CH(OCOCH₃)CH(OCOCH₃)CH₃, -CH₃, -CH₂OH or a phenyl group when R¹ and R² each represents a hydrogen atom, or -COCH(OH)CH₃ when R¹ and R² together represent a single bond or its pharmaceutically acceptable salt.

- ± **Prior Art**
- ± **Summary of the Invention**
- ± **Detailed Description of the Invention**
- ± **Examples**
- ± **Example 1 (Granules and fine granules)**
- ± **Example 2 (Tablets)**
- ± **Example 3 (Capsules)**
- ± **Example 4 (Injection)**
- ± **Example 5 (Injection)**
- ± **Example 6 (Suppositories)**
- ± **Example 7 (Granules)**
- ± **Example 8 (Granules)**
- ± **Example 9 (Granules)**
- ± **(Preliminary study)**

- ± **1. Clinical study:**
- ± **2. Biochemical study to clarify the mechanisms of pharmacological actions**
- ± **(1) Before treatment with S-T preparation:**
- ± **(2) After treatment with S-T preparation.**
- ± **(Therapeutic Example)**
- ± **<Subjects and Methods>**
- ± **1. Subjects**
- ± **2. Treatment period**
- ± **3. Dosage**
- ± **4. Evaluation methods**
- ± **a. Subjective improvement**
- ± **b. Neurological examination**
- ± **c. Timed tests**
- ± **5. Study design**
- ± **6. Statistical analysis**
- ± **<Results>**
- ± **1. Subjective symptoms**
- ± **2. Objective findings**
- ± **(1) Neurological checkup**
- ± **(2) Timed tests**
- ± **<Conclusion>**

Other Abstract Info:

CHEMABS 124(26)352702J DERABS C1996-129111



[Nominate this for the Gallery...](#)





[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)